Document Detail


Effects of bosentan on neointimal response following coronary angioplasty.
MedLine Citation:
PMID:  12925035     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Endothelins are important vasoconstrictors and cellular-growth promoters. ETA-specific antagonists have been shown to reduce neointimal response to injury in some experimental angioplasty models. However, there is little information on the effects of dual ETA/ETB receptor blockers, such as bosentan, on neointimal proliferation following experimental coronary angioplasty.
MATERIALS AND METHODS: Coronary injury was achieved by directional atherectomy in the left anterior descending artery of 20 pigs. Animals were randomly assigned to receive a daily dose of oral bosentan (30 mg kg-1) (group I, n = 10) or no treatment (group II, n = 10). At 4 weeks, arteries were processed for histomorphometry and endothelin characterization.
RESULTS: Vessel injury score was similar among the two groups. Overall, a linear correlation was found between injury and neointimal development (r = 0.57, P = 0.01). This correlation had a lower slope in group I compared with group II (P < 0.001), indicating a smaller amount of neointimal development for a similar degree of injury in bosentan-treated animals. Multivariate regression showed that neointimal response was reduced by oral treatment with bosentan (beta: -0.59 mm2, 95% CI: -1.11/-0.06 mm2). In addition, immunostaining revealed fewer positive endothelin areas in group I arteries.
CONCLUSIONS: Oral treatment with bosentan reduces neointimal development following coronary angioplasty in this experimental model.
Authors:
M Sanmartín; A Fernández-Ortiz; P Fantidis; P Aragoncillo; R Fernández-Durango; R Rollín; F Alfonso; R Hernández; J Escaned; C Macaya
Related Documents :
3994445 - Phrenic nerve injury complicating closed cardiovascular surgical procedures for congeni...
11499755 - Prevention of intimal hyperplasia with recombinant soluble p-selectin glycoprotein liga...
18953525 - Protective effects of glycyrrhizin in a gut hypoxia (ischemia)-reoxygenation (reperfusi...
19077655 - Endovascular stenting for the treatment of traumatic internal carotid injuries: expandi...
11479935 - Pathophysiology of calcium deposition in coronary arteries.
18162895 - Selective versus routine intraoperative shunting during carotid endarterectomy: a multi...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  European journal of clinical investigation     Volume:  33     ISSN:  0014-2972     ISO Abbreviation:  Eur. J. Clin. Invest.     Publication Date:  2003 Sep 
Date Detail:
Created Date:  2003-08-19     Completed Date:  2003-11-07     Revised Date:  2013-06-18    
Medline Journal Info:
Nlm Unique ID:  0245331     Medline TA:  Eur J Clin Invest     Country:  England    
Other Details:
Languages:  eng     Pagination:  762-8     Citation Subset:  IM    
Affiliation:
Cardiovascular Institute, San Carlos University Hospital, Madrid, Spain. marcelo.sanmartin.fernandez@sergas.es
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Angioplasty / methods*
Animals
Antihypertensive Agents / administration & dosage,  pharmacology*
Coronary Restenosis / etiology,  physiopathology
Coronary Vessels / drug effects*
Disease Models, Animal
Endothelin-1 / analysis
Hemodynamics / drug effects
Immunohistochemistry / methods
Receptors, Endothelin / antagonists & inhibitors
Sulfonamides / administration & dosage,  pharmacology*
Swine
Tunica Intima / drug effects*
Chemical
Reg. No./Substance:
0/Antihypertensive Agents; 0/Endothelin-1; 0/Receptors, Endothelin; 0/Sulfonamides; Q326023R30/bosentan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Marked increase in vascular endothelial growth factor concentrations during Escherichia coli endotox...
Next Document:  Mechanisms of renal hyporesponsiveness to ANP in heart failure.